GSK and Spero Therapeutics have scor | Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for complicated urinary tract infections, the company and its partner GSK have pushed Utebzi across the finish line.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery…
Two months after UCB revealed the success of Bimzelx in a head-to-head trial aga | Two months after UCB revealed the success of…
FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late 2026. See market reaction.
A combination of Merck’s islatravir and Gilead’s lenacapavir has
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug…
